Integrated Control Architectures: Transitioning from Batch-Based to Continuous Buffer Management in Biologics Manufacturing

The biopharmaceutical sector is witnessing major changes in its underlying structure. Although the “biologics revolution” has brought about the availability of life-saving monoclonal antibodies and gene therapies, the creation of production facilities has lagged behind to cope with the complexity of contemporary biologics. Generally, in the industry, inefficiencies, especially in handling process liquids such as buffers used for purification and formulation, have been present for many years and are even part of people’s way of working in manufacturing.

The traditional use of buffers is primarily a batch method, wherein large volumes are produced, stored in stainless-steel tanks, and after a short stability window, usually seven days or less, they are discarded. This model, though widely acknowledged because of regulatory expectations and operational habits, still results in recurring pressure points in capital, labor, and utility resources. A recent engineering advancement at a major U.S. biomanufacturing site demonstrates that these constraints can be addressed through advanced control theory and Real‑Time Buffer Batch Top‑Up (RBTU) control.

The Engineering Challenge: The Stability‑Waste Paradox

In a Good Manufacturing Practice (GMP) environment, consistency is the primary mandate. Buffers must maintain precise chemical profiles: pH, conductivity, and osmolality, to ensure protein stability and high‑resolution separation during chromatography. Because these liquids are susceptible to microbial growth and chemical drift, regulatory filings impose strict expiration dates.

When a buffer batch expires, the entire volume is flushed, the tank undergoes a Clean-in-Place (CIP) and Steam-in-Place (SIP) cycle, and a new batch is prepared. This “Stability-Waste Paradox” means that as production scales, a facility must either build more tanks (high CAPEX) or accept more frequent downtime (low OPEX efficiency). For years, the industry accepted this limitation as an unavoidable cost of compliance, and most facilities addressed it only through larger storage capacity or additional buffer preparation cycles.

Conceiving the RBTU Architecture

The shift toward a different model was led by Abantika Ghosh, a Lead Engineer with a background in computer engineering and process automation. Rather than optimizing the existing batch workflow, she reframed the problem itself, identifying buffer inefficiency not as a chemistry limitation but as a control systems challenge. Treating the buffer as a dynamic system rather than a static material with a fixed lifespan made it possible to maintain freshness and stability through continuous regulation.

Her approach introduced a real-time buffer batch top-up control architecture that fundamentally differed from conventional methods. Instead of discarding entire batches and restarting the cycle, the buffer tank was reimagined as a steady-state controlled reactor. Consumed volume is continuously replenished with concentrated stock solutions and high‑purity water while automated control loops maintain chemical balance. This transforms buffer management from a discrete batch process into a continuously regulated system.

Technical Framework and Logic Design

Implementing the system in a GMP facility required deeper control integration than typical buffer operations. Abantika spearheaded and architected the development of a multi‑variable control logic that evaluates more than 25 interacting process variables simultaneously through a nested control strategy.

1. The Inner Loop: High‑speed sensors continuously monitor pH and conductivity at the tank outlet. pH is maintained within ±0.05 units while conductivity is controlled within ±2%.
2. The Outer Loop: An embedded algorithm calculates replenishment requirements based on downstream purification consumption rates.
3. Active PAT Integration: Process Analytical Technology (PAT) signals were integrated directly into the control loop rather than used only for monitoring. Live data enables predictive adjustments before the buffer drifts outside specifications.

The control logic was developed in‑house, ensuring the system’s decision framework remained transparent and auditable for regulatory review.

Quantifiable Gains: Metrics of Success

The impact of the RBTU architecture was measurable upon deployment. By moving away from discrete batches, the facility achieved a state of pseudo-continuous buffer availability.

Operational Efficiency

Manufacturing data showed the usable lifetime of a buffer batch extended from about 5 days to nearly 30 days. This six‑fold increase significantly reduced tank turnovers and shortened buffer changeover downtime, from 48–72 hours to only a few hours.

Resource and Environmental Impact

The environmental footprint of the facility improved. Internal audits following the implementation recorded double-digit percentage reductions in the consumption of:

• Water for Injection (WFI): Reduced by eliminating frequent tank rinsing and full-volume batch replacements.
• Chemical Cleaning Agents: Decreased as a result of fewer CIP cycles.
• Steam and Electricity: Lowered demand for sterilization and thermal regulation of storage tanks.

Capital Expenditure (CAPEX) Avoidance

The efficiency gains eliminated the need for planned installation of an additional 10,000‑liter buffer tanks. By increasing the effective capacity of existing infrastructure, the facility avoided a multi‑million‑dollar capital expansion.

Navigating the Regulatory Landscape

Innovation in biopharma is often constrained by regulatory risk, particularly for continuous processes where batch definition and traceability are closely scrutinized. Abantika addressed this by embedding documentation, monitoring, and failsafe logic directly into the system architecture.

Automated deviation triggers ensured that if any Critical Quality Attribute approached a limit, the buffer would be automatically isolated from production. At the same time, real‑time data logging created a complete digital record of buffer conditions, providing traceability that exceeded traditional manual sampling.

This design demonstrated that a continuous top‑up model could meet, and in some cases surpass, the documentation and control standards of conventional batch manufacturing.

As Abantika explains, “The goal was never simply to extend the shelf life of buffers. The real objective was to remove a long-standing, artificial constraint that the industry had accepted for decades and allow manufacturing systems to operate at the level they are inherently capable of, efficiently, predictably, and under full regulatory compliance.”

Industry Significance

The broader significance of this achievement lies in its scalability. While optimized for a specific biologics site, the underlying philosophy replaces physical expansion with advanced software control. Following its implementation, similar control‑driven approaches to buffer management have been examined and referenced by process scientists and engineering teams across multiple biopharmaceutical organizations facing comparable operational constraints.

The impact of the architecture is most clearly reflected in its measurable outcomes. By eliminating the need for additional large‑scale buffer infrastructure and avoiding a multi‑million‑dollar capital expansion, the system demonstrated that advanced control strategies can directly translate into tangible operational and financial value. In doing so, it challenges long‑held assumptions within biologics manufacturing that reliability must be tied to rigid, resource‑intensive batch processes.

As the industry moves toward “Factory of the Future” concepts defined by modularity and digitalization, the RBTU control architecture serves as a useful case study. It reflects a shift from “building more” to “thinking smarter,” applying computer engineering principles to the physical constraints of pharmaceutical production.

Conclusion

The transition from batch‑based to continuous buffer management represents more than an incremental improvement; it signals a shift in biologics manufacturing strategy. Through the development of the real‑time buffer batch top‑up control architecture, Abantika Ghosh demonstrated how digital control systems can enhance operational efficiency and sustainability.

In an industry where the stakes involve patient outcomes and major financial investment, such advances show that modernization grounded in rigorous engineering is both achievable and necessary.